Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial - PR Newswire

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial    PR Newswire Eli Lilly says next-generation weight loss drug clears crucial obesity trial    CNBC Experimental Drug Yields Dramatic Weight Loss    The New York Times Experimental Lilly drug reaches surgery-level weight loss    Axios Lilly’s Experimental Shot Cuts Body Weight by 28% in Study    Bloomberg.com

Original source: Google News